164 related articles for article (PubMed ID: 2386983)
1. Indomethacin modulation of adriamycin-induced effects on multiple cytolytic effector functions.
Maccubbin DL; Cohen SA; Ehrke MJ
Cancer Immunol Immunother; 1990; 31(6):373-80. PubMed ID: 2386983
[TBL] [Abstract][Full Text] [Related]
2. Prostaglandin E2-mediated inactivation of various killer lineage cells by tumor-bearing host macrophages.
Parhar RS; Lala PK
J Leukoc Biol; 1988 Dec; 44(6):474-84. PubMed ID: 2973508
[TBL] [Abstract][Full Text] [Related]
3. Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer.
Baxevanis CN; Reclos GJ; Gritzapis AD; Dedousis GV; Missitzis I; Papamichail M
Cancer; 1993 Jul; 72(2):491-501. PubMed ID: 8319179
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy-induced modulation of natural killer and lymphokine-activated killer cell activity in euthymic and athymic mice.
Gazit Z; Kedar E
Cancer Immunol Immunother; 1994 Apr; 38(4):243-52. PubMed ID: 8168119
[TBL] [Abstract][Full Text] [Related]
5. Activity inhibition of cytolytic lymphocytes by omeprazole.
Scaringi L; Cornacchione P; Fettucciari K; Rosati E; Rossi R; Marconi P; Capodicasa E
Scand J Immunol; 1996 Sep; 44(3):204-14. PubMed ID: 8795713
[TBL] [Abstract][Full Text] [Related]
6. Comparison of adriamycin induced immunomodulation with that of the noncardiotoxic anthracycline 5-iminodaunorubicin.
Maccubbin DL; Whitman JA; Taniguchi N; Mace KF; Ehrke MJ; Mihich E
Int J Immunopharmacol; 1988; 10(3):317-23. PubMed ID: 3263335
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of murine lymphokine-activated killer (LAK) cell activity by adherent cells.
Longley RE; Stewart D; Roe KG; Good RA
Cell Immunol; 1989 Jul; 121(2):225-36. PubMed ID: 2786756
[TBL] [Abstract][Full Text] [Related]
8. Alterations in murine host defense functions by adriamycin or liposome-encapsulated adriamycin.
Mace K; Mayhew E; Mihich E; Ehrke MJ
Cancer Res; 1988 Jan; 48(1):130-6. PubMed ID: 3257160
[TBL] [Abstract][Full Text] [Related]
9. Prostaglandin E2 from macrophages of murine splenocyte cultures inhibits the generation of lymphokine-activated killer cell activity.
Ohnishi H; Lin TH; Nakajima I; Chu TM
Tumour Biol; 1991; 12(2):99-110. PubMed ID: 2028183
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of human NK cell and LAK cell cytotoxicity and differentiation by PGE2.
Leung KH
Cell Immunol; 1989 Oct; 123(2):384-95. PubMed ID: 2507171
[TBL] [Abstract][Full Text] [Related]
11. Doxorubicin plus tumor necrosis factor alpha combination treatments in EL4-lymphoma-bearing C57BL/6 mice.
Ehrke MJ; Verstovsek S; Ujházy P; Meer JM; Eppolito C; Maccubbin DL; Mihich E
Cancer Immunol Immunother; 1998 Feb; 45(6):287-98. PubMed ID: 9490198
[TBL] [Abstract][Full Text] [Related]
12. Indomethacin up-regulates the generation of lymphokine-activated killer-cell activity and antibody-dependent cellular cytotoxicity mediated by interleukin-2.
Eisenthal A
Cancer Immunol Immunother; 1990; 31(6):342-8. PubMed ID: 2386979
[TBL] [Abstract][Full Text] [Related]
13. Activation of natural killer-derived cytotoxic T lymphocytes. I. Regulation by macrophage and prostaglandins.
Ting CC; Hargrove ME
J Immunol; 1983 Oct; 131(4):1734-41. PubMed ID: 6604751
[TBL] [Abstract][Full Text] [Related]
14. Adriamycin-induced activation of NK activity may initially involve LAF production.
Cohen SA; Salazar D; Wicher J
Cancer Immunol Immunother; 1983; 15(3):188-93. PubMed ID: 6193867
[TBL] [Abstract][Full Text] [Related]
15. The augmentation of lymphokine-activated killer cell activity by indomethacin in vitro is not mediated by prostaglandin E2 suppression.
Chao TY; Ting CS; Chu TM; Yeh MY
Proc Natl Sci Counc Repub China B; 1993 Oct; 17(4):138-42. PubMed ID: 8171164
[TBL] [Abstract][Full Text] [Related]
16. Dimethyl 2,2-dichlorovinyl phosphate (DDVP) markedly inhibits activities of natural killer cells, cytotoxic T lymphocytes and lymphokine-activated killer cells via the Fas-ligand/Fas pathway in perforin-knockout (PKO) mice.
Li Q; Nakadai A; Takeda K; Kawada T
Toxicology; 2004 Nov; 204(1):41-50. PubMed ID: 15369847
[TBL] [Abstract][Full Text] [Related]
17. Augmentation of murine lymphokine (rIL-2)-activated killer cell activity by indomethacin.
Chao TY; Ohnishi H; Chu TM
Mol Biother; 1989; 1(6):318-22. PubMed ID: 2610950
[TBL] [Abstract][Full Text] [Related]
18. Effects of adriamycin on the activity of mouse natural killer cells.
Santoni A; Riccardi C; Sorci V; Herberman RB
J Immunol; 1980 May; 124(5):2329-35. PubMed ID: 6444969
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
Kalland T; Belfrage H; Bhiladvala P; Hedlund G
J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566
[TBL] [Abstract][Full Text] [Related]
20. In vivo boosting of lung natural killer and lymphokine-activated killer cell activity by interleukin-2: comparison of systemic, intrapleural and inhalation routes.
Flexman JP; Manning LS; Robinson BW
Clin Exp Immunol; 1990 Oct; 82(1):151-6. PubMed ID: 2208789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
